124 related articles for article (PubMed ID: 38268917)
1. Corrigendum: Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients.
Jiménez-Ubieto A; Martín-Muñoz A; Poza M; Dorado S; García-Ortiz A; Revilla E; Sarandeses P; Ruiz-Heredia Y; Baumann T; Rodríguez A; Calbacho M; Sánchez PM; Pina JMS; García-Sancho AM; Figaredo G; Gil-Alós D; Rufián L; Rodríguez M; Carneros L; Martínez-Laperche C; Bastos-Oreiro M; Wang C; Cedena MT; Rapado I; de Toledo P; Gallardo M; Valeri A; Ayala R; Martínez-López J; Barrio S
Front Immunol; 2023; 14():1349296. PubMed ID: 38268917
[TBL] [Abstract][Full Text] [Related]
2. Corrigendum: Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients.
Jiménez-Ubieto A; Martín-Muñoz A; Poza M; Dorado S; García-Ortiz A; Revilla E; Sarandeses P; Ruiz-Heredia Y; Baumann T; Rodríguez A; Calbacho M; Sánchez PM; Pina JMS; García-Sancho AM; Figaredo G; Rufián L; Rodríguez M; Carneros L; Martínez-Laperche C; Bastos-Oreiro M; Wang C; Cedena MT; Rapado I; de Toledo P; Gallardo M; Valeri A; Ayala R; Martínez-López J; Barrio S
Front Immunol; 2023; 14():1243241. PubMed ID: 37662957
[TBL] [Abstract][Full Text] [Related]
3. Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients.
Jiménez-Ubieto A; Martín-Muñoz A; Poza M; Dorado S; García-Ortiz A; Revilla E; Sarandeses P; Ruiz-Heredia Y; Baumann T; Rodríguez A; Calbacho M; Sánchez PM; Pina JMS; García-Sancho AM; Figaredo G; Rufián L; Rodríguez M; Carneros L; Martínez-Laperche C; Bastos-Oreiro M; Wang C; Cedena MT; Rapado I; de Toledo P; Gallardo M; Valeri A; Ayala R; Martínez-López J; Barrio S
Front Immunol; 2023; 14():1188818. PubMed ID: 37342332
[TBL] [Abstract][Full Text] [Related]
4. Serial surveillance by circulating tumor DNA profiling after chimeric antigen receptor T therapy for the guidance of r/r diffuse large B cell lymphoma precise treatment.
Zhou L; Zhao H; Shao Y; Chen X; Hong R; Wang L; Ni F; Nagler A; Hu Y; Huang H
J Cancer; 2021; 12(18):5423-5431. PubMed ID: 34405005
[No Abstract] [Full Text] [Related]
5. [Analysis of the feasibility and prognostic value of circulating tumor DNA monitoring in detecting gene mutations in patients with diffuse large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy].
Zhou LH; Feng YQ; Hu YX; Huang H
Zhonghua Xue Ye Xue Za Zhi; 2023 Oct; 44(10):805-812. PubMed ID: 38049331
[No Abstract] [Full Text] [Related]
6. Circulating Tumor DNA in Lymphoma.
Kambhampati S; Zain J
Curr Hematol Malig Rep; 2022 Dec; 17(6):298-305. PubMed ID: 36214943
[TBL] [Abstract][Full Text] [Related]
7.
Chen L; Mu W; Gu J; Xiao M; Huang L; Zheng M; Li C; Xiao Y; Zhou J; Long X
Diagnostics (Basel); 2021 May; 11(5):. PubMed ID: 34066756
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Impact of 18F-FDG PET/CT in Patients With Aggressive B-Cell Lymphoma Treated With Anti-CD19 Chimeric Antigen Receptor T Cells.
Sesques P; Tordo J; Ferrant E; Safar V; Wallet F; Dhomps A; Brisou G; Bouafia F; Karlin L; Ghergus D; Golfier C; Lequeu H; Lazareth A; Vercasson M; Hospital-Gustem C; Schwiertz V; Choquet M; Sujobert P; Novelli S; Mialou V; Hequet O; Carras S; Fouillet L; Lebras L; Guillermin Y; Leyronnas C; Cavalieri D; Janier M; Ghesquières H; Salles G; Bachy E
Clin Nucl Med; 2021 Aug; 46(8):627-634. PubMed ID: 34115706
[TBL] [Abstract][Full Text] [Related]
9. Next-generation sequencing-based detection of circulating tumour DNA After allogeneic stem cell transplantation for lymphoma.
Herrera AF; Kim HT; Kong KA; Faham M; Sun H; Sohani AR; Alyea EP; Carlton VE; Chen YB; Cutler CS; Ho VT; Koreth J; Kotwaliwale C; Nikiforow S; Ritz J; Rodig SJ; Soiffer RJ; Antin JH; Armand P
Br J Haematol; 2016 Dec; 175(5):841-850. PubMed ID: 27711974
[TBL] [Abstract][Full Text] [Related]
10. Circulating tumor DNA by high-throughput sequencing of T cell receptor monitored treatment response and predicted treatment failure in T cell lymphomas.
Zhang W; Wang W; Han X; Gan Y; Qian L; Zhang Y; Zhang C; Wang Y; Guan Y; Yang L; Zhou D
Int J Lab Hematol; 2021 Oct; 43(5):1041-1049. PubMed ID: 33734593
[TBL] [Abstract][Full Text] [Related]
11. Tumor Burden Measured by 18F-FDG PET/CT in Predicting Efficacy and Adverse Effects of Chimeric Antigen Receptor T-Cell Therapy in Non-Hodgkin Lymphoma.
Hong R; Tan Su Yin E; Wang L; Zhao X; Zhou L; Wang G; Zhang M; Zhao H; Wei G; Wang Y; Wu W; Zhang Y; Ni F; Hu Y; Huang H; Zhao K
Front Oncol; 2021; 11():713577. PubMed ID: 34422666
[TBL] [Abstract][Full Text] [Related]
12. Liquid biopsy for disease monitoring after anti-CD19 chimeric antigen receptor T cell in diffuse large B-cell lymphoma.
Maluquer C; Bellosillo B; Mussetti A; Domingo-Domènech E; Parody R; Fernández-Ibarrondo L; Velasco R; Moreno-González G; Sanz G; Cortés M; Sureda A
EJHaem; 2021 Feb; 2(1):109-111. PubMed ID: 35846093
[TBL] [Abstract][Full Text] [Related]
13. Early 18F-FDG PET Flare-up Phenomenon After CAR T-Cell Therapy in Lymphoma.
Boursier C; Perrin M; Bordonne M; Campidelli A; Verger A
Clin Nucl Med; 2022 Feb; 47(2):e152-e153. PubMed ID: 34406181
[TBL] [Abstract][Full Text] [Related]
14. Corrigendum: Chimeric Antigen Receptors T Cell Therapy in Solid Tumor: Challenges and Clinical Applications.
Mirzaei HR; Rodriguez A; Shepphird J; Brown CE; Badie B
Front Immunol; 2019; 10():780. PubMed ID: 31049049
[TBL] [Abstract][Full Text] [Related]
15. Circulating Tumor DNA to Monitor Therapy for Aggressive B-Cell Lymphomas.
Kwok M; Wu SP; Mo C; Summers T; Roschewski M
Curr Treat Options Oncol; 2016 Sep; 17(9):47. PubMed ID: 27461036
[TBL] [Abstract][Full Text] [Related]
16. Integration of molecular testing for the personalized management of patients with diffuse large B-cell lymphoma and follicular lymphoma.
Stuckey R; Luzardo Henríquez H; de la Nuez Melian H; Rivero Vera JC; Bilbao-Sieyro C; Gómez-Casares MT
World J Clin Oncol; 2023 Apr; 14(4):160-170. PubMed ID: 37124135
[TBL] [Abstract][Full Text] [Related]
17. Assessment of treatment responses in children and adolescents with Ewing sarcoma with metabolic tumor parameters derived from
Schmidkonz C; Krumbholz M; Atzinger A; Cordes M; Goetz TI; Prante O; Ritt P; Schaefer C; Agaimy A; Hartmann W; Rössig C; Fröhlich B; Bäuerle T; Dirksen U; Kuwert T; Metzler M
Eur J Nucl Med Mol Imaging; 2020 Jun; 47(6):1564-1575. PubMed ID: 31853559
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of baseline and early response FDG-PET/CT in patients with refractory and relapsed aggressive B-cell lymphoma undergoing CAR-T cell therapy.
Georgi TW; Kurch L; Franke GN; Jentzsch M; Schwind S; Perez-Fernandez C; Petermann N; Merz M; Metzeler K; Borte G; Hoffmann S; Herling M; Denecke T; Kluge R; Sabri O; Platzbecker U; Vučinić V
J Cancer Res Clin Oncol; 2023 Aug; 149(9):6131-6138. PubMed ID: 36662305
[TBL] [Abstract][Full Text] [Related]
19. High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program.
Park S; Olsen S; Ku BM; Lee MS; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Ahn MJ
Cancer; 2021 Aug; 127(16):3019-3028. PubMed ID: 33826761
[TBL] [Abstract][Full Text] [Related]
20. Whole-genome informed circulating tumor DNA analysis by multiplex digital PCR for disease monitoring in B-cell lymphomas: a proof-of-concept study.
Haider Z; Wästerlid T; Spångberg LD; Rabbani L; Jylhä C; Thorvaldsdottir B; Skaftason A; Awier HN; Krstic A; Gellerbring A; Lyander A; Hägglund M; Jeggari A; Rassidakis G; Sonnevi K; Sander B; Rosenquist R; Tham E; Smedby KE
Front Oncol; 2023; 13():1176698. PubMed ID: 37333831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]